What Immunovant, Inc. told the SEC could break it.

Immunovant flags exposure to U.S.–China trade and biotech-decoupling policy: in April 2025 the U.S. and China implemented reciprocal tariffs on a variety of goods including pharmaceutical products, and U.S./China rules could impair the ability of U.S. biotechnology companies to partner with entities in China. It conducts certain laboratory research and expects clinical-trial sites in Asia, and its suppliers source components/raw materials in regions exposed to trade measures — leaving it open to product-supply disruption, clinical-trial delays and increased costs from changing trade policy (its core assets are also in-licensed from Korea's HanAll). A specific U.S.–China/Asia trade-policy exposure relevant to the supply-shock thesis.

“in April 2025, the U.S. and China implemented reciprocal tariffs on a variety of goods, including pharmaceutical products.”

Immunovant is a clinical-stage biopharma that depends entirely on third-party manufacturers and suppliers to produce its anti-FcRn antibody candidates (batoclimab, IMVT-1402). It flags a lack of qualified backup suppliers for components currently purchased from a sole or single source supplier, and that its third-party manufacturers/suppliers could be disrupted by events unrelated to its business (bankruptcy, regulatory sanctions tied to another company's products, carrier disruptions, or storage/delivery failures), which could cause clinical-trial delays, cost overruns or supply interruptions. A structural sole-source manufacturing dependence typical of — and material to — a no-in-house-manufacturing biologics developer.

“lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier”